- The trend backdrop is active with a 6-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
INDOCO
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Indoco Remedies Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
221.7 INR
1.0%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 2.8% above the Trend Line and sits at 35.0% of its 52-week range. The latest completed week returned 1.0%, after a -14.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal.
Setup score
26
out of 100
Latest Close
221.7 INR
7 Aug 2026
1W Return
1.0%
latest completed week
4W Return
-14.8%
short-term follow-through
12W Return
-1.4%
quarterly tape
Trend Breadth
34.6%
18 of 52 weeks active
Volume Ratio
0.4x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 41.33% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.0%
Latest completed week; four-week move -14.8%.
Indicator stack
40/60
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 41.33%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
49/100
7 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 2.8% above the Trend Line and sits at 35.0% of its 52-week range. The latest completed week returned 1.0%, after a -14.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4012-week average 0.20
12-week confirmation
Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.40Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -14.8% over four weeks, -1.4% over 12 weeks, and -24.0% over one year. The current trend has remained active for 6 consecutive weeks.
Performance by holding period
Active trend streak6 weeks
Active weeks in one year18
Trend breadth34.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.74Latest activity-pressure read.
Pressure change-41.0%Four-week change in activity pressure.
Leadership-5.65Latest relative-leadership reading.
RS change-157.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 85%
Model confidence 79%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength17/100Blend of value, momentum, and quality. Underlying universe rank 84; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality33/100Profitability and accounting quality. Underlying universe rank 68; rank 1 is best.
Momentum20/100Medium-term price momentum. Underlying universe rank 81; rank 1 is best.
Growth37/100Revenue and earnings growth. Underlying universe rank 64; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 1.1x Market value relative to trailing revenue.
- EV / EBITDA
- 21.9x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 3.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 69.8% Gross profit retained from each unit of revenue.
- Operating margin
- 0.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 5.6% Free cash flow generated from revenue.
- Return on invested capital
- 0.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 9.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.1% Cash dividends relative to market value.
- Buyback yield
- -0.1% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 7.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment49/100
Weighted news tone is neutral across 7 relevant articles.
1 positive · 5 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-33.3%Distance below the 52-week high.
13-week volatility7.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+20.3%Week of 12 Jun.
Worst week-11.5%Week of 22 May.
Latest week+1.0%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains3
Flat weeks0
Modest losses8
Sharp losses7
Recent vol7.9%13-week weekly-return volatility.
Base vol5.5%52-week weekly-return volatility.
Up/down split19/33Count of positive and negative weeks in the 52-week window.
Average skew5.0% / -3.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank89 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape30/100
Trend, activity pressure, participation, and risk combine to a 30/100 tape read.
Indicator analysis57/100Latest 12-week confirmation: trend 6/12, activity pressure 12/12, relative leadership 5/12.
Activity pressure 0.40; No reversal markers Next-Week ExpectancyNegative 41.33%Next-week expectancy is negative with a 41.33% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors27/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 76; Small Cap Core rank 40 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment49/100Weighted news tone is neutral across 7 relevant articles.
Indoco Remedies cuts debt to ₹930 crore, targets double-digit EBITDA margins Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 221.7 INR | 1.0% | 215.6 INR | 291.1 INR | 0.74 | -5.65 | 451.7K | On |
| 31 Jul 2026 | 219.5 INR | -9.8% | 215.5 INR | 291.8 INR | 1.08 | -6.44 | 5.8M | On |
| 24 Jul 2026 | 243.4 INR | -1.6% | 215.7 INR | 292.5 INR | 1.22 | 5.69 | 331.0K | On |
| 17 Jul 2026 | 247.4 INR | -4.9% | 215.1 INR | 292.9 INR | 1.26 | 4.42 | 611.7K | On |
| 10 Jul 2026 | 260.2 INR | 6.7% | 214.9 INR | 293.4 INR | 1.25 | 9.78 | 1.3M | On |
| 3 Jul 2026 | 244.0 INR | 5.4% | 214.3 INR | 293.8 INR | 1.28 | 2.22 | 119.3K | On |
| 26 Jun 2026 | 231.6 INR | -1.4% | 214.5 INR | 294.3 INR | 1.09 | -2.72 | 0 | Off |
| 19 Jun 2026 | 235.0 INR | -5.6% | 215.4 INR | 294.9 INR | 1.15 | -1.53 | 127.8K | Off |
| 12 Jun 2026 | 248.8 INR | 20.3% | 216.1 INR | 295.4 INR | 1.02 | 5.66 | 4.2M | Off |
| 5 Jun 2026 | 206.8 INR | -1.3% | 216.6 INR | 295.9 INR | 0.89 | -11.34 | 101.2K | Off |
| 29 May 2026 | 209.7 INR | 5.3% | 218.4 INR | 296.7 INR | 1.12 | -11.19 | 1.9M | Off |
| 22 May 2026 | 199.1 INR | -11.5% | 220.7 INR | 297.6 INR | 0.98 | -16.47 | 331.8K | Off |
| 15 May 2026 | 224.9 INR | -1.3% | 223.4 INR | 298.4 INR | 0.95 | -5.59 | 435.3K | Off |
| 8 May 2026 | 227.9 INR | 8.8% | 225.4 INR | 299.2 INR | 0.89 | -6.54 | 1.9M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.